Day One Biopharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE, CA, 94005
Mailing Address
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE, CA, 94005
Phone
650 484-0899
Fiscal Year End
1231
EIN
832415215
Financial Overview
FY2025 FY
$158.18M
Revenue
$582.79M
Total Assets
$502.75M
Stockholders' Equity
$197.08M
Cash & Equivalents
$-1.02
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 19, 2026 | View on SEC |
| 8-K/A Current report amendment | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| 10-K Annual financial report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
Insider Trading
SELL
5 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.